Blog
RSS FeedPosted by Michael Wonder on 28 Oct 2020
Forxiga cardiovascular outcomes benefit approved in China
28 October 2020 - Update to approval includes DECLARE-TIMI 58 Phase 3 trial that reduced the risk of composite of hospitalisation ...
Posted by Michael Wonder on 21 Oct 2020
Priority review granted to Ascentage Pharma's new drug application for olverembatinib (HQP1351), the first third generation BCR-ABL inhibitor in China
21 October 2020 - Ascentage Pharma today announced that the Center for Drug Evaluation of China's National Medical Products Administration has ...
Posted by Michael Wonder on 12 Oct 2020
Innovent and Lilly jointly announce the NMPA granted marketing approval for Halpryza (rituximab injection) in China
9 October 2020 - Innovent Biologics and Eli Lilly and Company today jointly announce that Halpryza (rituximab injection), a recombinant human/murine ...
Posted by Michael Wonder on 05 Oct 2020
Physician–patient shared decision making, patient satisfaction, and adoption of new health technology in China
2 October 2020 - A cross-sectional study was conducted from July 2016 to October 2016 in Fujian Province and Shanghai, in ...
Posted by Michael Wonder on 28 Sep 2020
International experience with performance-based risk-sharing arrangements: implications for the Chinese innovative pharmaceutical market
23 September 2020 - This study aims to summarise the international experience of performance-based risk-sharing arrangements and identify the preconditions for ...
Posted by Michael Wonder on 18 Sep 2020
Chi-Med announces second NDA acceptance in China for surufatinib in pancreatic neuroendocrine tumours
17 September 2020 - Hutchison China MediTech today announces that its new drug application for surufatinib for the treatment of ...
Posted by Michael Wonder on 09 Sep 2020
CANbridge Pharmaceuticals receives Chinese marketing approval for Hunterase first enzyme replacement therapy for Hunter syndrome in China
9 September 2020 - CANbridge Pharmaceuticals announced that it received marketing approval from China’s National Medical Products Administration for Hunterase (idursulfase ...
Posted by Michael Wonder on 04 Sep 2020
Innovent announces NMPA granted marketing approval for Sulinno (adalimumab injection) in China
Innovent Biologics today announced that Sulinno (adalimumab injection), a recombinant human anti-TNF-α monoclonal antibody drug, has been officially approved by ...
Posted by Michael Wonder on 20 Aug 2020
Drug makers slash prices to win China's bulk-buy contracts
20 August 2020 - Drug makers have slashed prices by up to 95% to win state contracts in China's largest ...
Posted by Michael Wonder on 18 Aug 2020
China's first trastuzumab biosimilar approved by NMPA
17 August 2020 - Shanghai Henlius Biotech announced on 14 August that the trastuzumab biosimilar HLX02, developed and manufactured by Henlius ...
Posted by Michael Wonder on 13 Aug 2020
Innovent and Eli Lilly announce acceptance of a supplemental new drug application of Tyvyt (sintilimab injection) in combination with gemcitabine and platinum as first-line therapy in squamous non-small cell lung cancer in China
12 August 2020 - Innovent Biologics today jointly announced with Eli Lilly that the National Medical Products Administration of China has ...
Posted by Michael Wonder on 11 Aug 2020
China National Medical Products Administration approves Truvada for HIV pre-exposure prophylaxis
11 August 2020 - Truvada is the first HIV PrEP medicine approved in China. ...
Posted by Michael Wonder on 06 Aug 2020
The China Center for Drug Evaluation, National Medical Products Administration has recommended breakthrough therapy designation for ciltacabtagene autoleucel, an investigational BCMA CAR-T Cell therapy
5 August 2020 - Legend Biotech announced today that the China Center for Drug Evaluation, National Medical Products Administration has recommended ...
Posted by Michael Wonder on 28 Jul 2020
Priority review granted to BeiGene’s new drug application of pamiparib in ovarian cancer in China
27 July 2020 - BeiGene today announced that the Center for Drug Evaluation of the China National Medical Products Administration has ...
Posted by Michael Wonder on 21 Jul 2020
China NMPA accepts NDA submission of ripretinib for advanced gastro-intestinal stromal tumour
20 July 2020 - China NMPA acceptance of NDA follows recent U.S. FDA approval for the treatment of adult patients ...